The mechanism of dapagliflozin is to promote glycemic disposal in an insulin-independent way, thereby decreasing postprandial glycemia and glycemic excursions accompanied by an inferior insulin demand without increasing the risk of hypoglycemia. Here, INS is linked to Hypoglycemia.